Autoimmune Collaboration and Licensing Deals 2016-2026

Description

Autoimmune Collaboration and Licensing Deals

Stop guessing autoimmune deal terms. Start using real evidence.

Autoimmune is one of the most competitive and fragmented partnering markets in biopharma - spanning 30+ diseases, multiple modalities, and highly variable deal structures.

If you're entering a deal without clear benchmarks, you're operating at a disadvantage.

This report gives you direct access to 1,000+ real-world autoimmune partnerships, so you can see exactly how deals are structured, valued, and negotiated across the market.

Know what a "market deal" actually looks like

Without real comparables, it's easy to overpay, undersell, or misjudge partner expectations.

With this report, you can:

Anchor your deal with real precedent
Understand what companies are actually agreeing to - not just what's announced
Benchmark financial terms with confidence
Compare upfronts, milestones, and royalty structures across autoimmune deals
Understand variability across indications and stages
See how deals differ between RA, IBD, dermatology, and beyond
Pressure-test your assumptions before negotiations
Validate your structure against real transactions
Go beyond headline numbers - see how deals are really done
Most sources stop at deal value. That's not enough.

This report gives you access to actual contract documents, so you can see:

What rights are granted (and retained)
How development and commercialization responsibilities are split
How payments are triggered in practice
Where risk, control, and flexibility sit in the agreement
Because in autoimmune dealmaking, the structure matters as much as the price.
Built for teams actively doing autoimmune deals

Whether you're licensing assets, partnering programs, or evaluating opportunities, this report helps you:

Move faster with instant access to relevant comparables
De-risk decisions using real deal evidence
Strengthen your negotiation position
Support internal strategy with credible market data
What you get
1,000+ autoimmune collaboration and licensing deals
Coverage across 30+ autoimmune diseases
Financial terms, including upfronts, milestones, and royalties
Fully searchable deal directory (by company, therapy, technology)
Direct access to SEC-filed contract documents
500+ pages of structured deal analysis
The bottom line
Autoimmune dealmaking is complex - but your decision-making doesn't have to be.
This report gives you the benchmarks, deal structures, and contract-level insight you need to structure better deals - and win them.
Request a sample or speak to us about how this can support your current autoimmune deal work.

Product Code: CP2228

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

2.1. Introduction
2.2. Autoimmune deals over the years
2.3. Autoimmune deals by deal type
2.4. Autoimmune deals by industry sector
2.5. Autoimmune deals by stage of development
2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

3.1. Introduction
3.2. Disclosed financials terms for autoimmune deals
3.3. Autoimmune deal headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

4.1. Introduction
4.2. Most active in autoimmune dealmaking
4.3. List of most active dealmakers in autoimmune
4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

5.1. Introduction
5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by autoimmune therapeutic target
Deal Directory
Deal Directory - Autoimmune deals by company A-Z
Deal Directory - Autoimmune deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Autoimmune deals since 2016
Figure 2: Autoimmune deals by deal type since 2016
Figure 3: Autoimmune deals by industry sector since 2016
Figure 4: Autoimmune deals by stage of development since 2016
Figure 5: Autoimmune deals by technology type since 2016
Figure 6: Autoimmune deals with a headline value
Figure 7: Autoimmune deals with upfront payment values
Figure 8: Autoimmune deals with milestone payment
Figure 9: Autoimmune deals with royalty rates
Figure 10: Active autoimmune dealmaking activity since 2016
Figure 11: Top autoimmune deals by value since 2016